8-K current report · filed Oct 28, 2026

MIMEDX GROUP, INC. (MDXG) 8-K Current Report: October 28, 2026

Item 2.02Item 7.01Item EX-99.1Item EX-99.3Item EX-99.2MDXG overview

Short answer

MIMEDX GROUP, INC. (MDXG) filed an 8-K current report with the SEC on October 28, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.3 (Exhibit EX-99.3), Item EX-99.2 (Exhibit EX-99.2). MiMedx announced second-quarter 2026 results on October 28, 2026.

MIMEDX GROUP, INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • MiMedx announced second-quarter 2026 results on October 28, 2026
  • Detailed financial results and management commentary are provided in Exhibit 99.1, the earnings press release

Item 7.01 · Regulation FD Disclosure

  • October 28, 2026 earnings call covering third-quarter 2026 financial and operating results
  • Investor presentation updated October 28, 2026, offering supplemental operating and strategic information
  • Exhibit 99.2 contains earnings-call slides, while Exhibit 99.3 contains updated investor materials

Item EX-99.1 · Exhibit EX-99.1

  • Q3 net sales $62.3M, down 45%, driven by Wound sales falling 71% despite Surgical sales growth of 9%
  • Adjusted EBITDA $2.1M, margin 3.3%, versus $35.0M and 30.7% prior year, showing severe earnings pressure
  • GAAP net loss $8.7M versus $16.7M profit, while SG&A fell to $58.3M after cost reductions
  • Cash $120.8M, with the remaining $17M term loan repaid and no debt outstanding
  • 2026 sales outlook reduced to $250M-$260M, while Sanara acquisition remains subject to FTC HSR clearance

Item EX-99.2 · Exhibit EX-99.2

  • Q3 net sales $62MM, with Surgical $40MM and Wound $22MM
  • Surgical volume growth reached mid-teens, while Wound Care Center volumes rose 7% sequentially and over 20% year-over-year
  • Adjusted EBITDA $2.1MM, margin 3.3%, versus $35.0MM and 30.7% in Q3 2025
  • AXIOFILL FDA classifications vacated and remanded, preserving regulatory pathway and commercial opportunity
  • Sanara deal faces additional FTC review, backed by committed $300MM term financing at Term SOFR plus 6.25%
  • 2026 net sales outlook $250–260MM, with Q4 Adjusted EBITDA expected to increase sequentially

Item EX-99.3 · Exhibit EX-99.3

  • Proposed Sanara acquisition values target at approximately $350 million, funded partly by a $300 million term loan and 4.4 million MDXG shares
  • Debt terms: six-year maturity at SOFR plus 6.25%, creating meaningful post-close interest and leverage exposure
  • Expected first-year combined revenue near $400 million, over $20 million annualized cost synergies in 2027, and adjusted EBITDA margin above 20%
  • FTC clearance remains the final major closing hurdle, leaving timing and completion risk unresolved
  • Q3 2026 net sales $62 million, adjusted EBITDA $2.1 million versus $35.0 million, with margin declining to 3.3% from 30.7%

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other MIMEDX GROUP, INC. 8-K filings

Get the next MDXG 8-K as it lands

Follow MDXG for push alerts, or ask the research agent what this filing means.